{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:08:21Z","timestamp":1778710101955,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["IPA \/2021\/000147"],"award-info":[{"award-number":["IPA \/2021\/000147"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bbrc.2026.153716","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:55:03Z","timestamp":1775098503000},"page":"153716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of single chain antibodies for targeting Ewing sarcoma surface marker CD99"],"prefix":"10.1016","volume":"816","author":[{"given":"Yogalakshmi","family":"Sabapathy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajkumar","family":"Thangarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazeer","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayanan","family":"Madaboosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-162X","authenticated-orcid":false,"given":"Guhan","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal","family":"Gopisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153716_bib1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s13205-024-03958-z","article-title":"Therapeutic proteins: developments, progress, challenges, and future perspectives","volume":"14","author":"Kumar","year":"2024","journal-title":"3 Biotech"},{"key":"10.1016\/j.bbrc.2026.153716_bib2","article-title":"Recombinant antibody fragment therapeutics: current status and future prospects of scFv, nanobody, and mimotopes","volume":"89","author":"Ghaderi","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2026.153716_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/antib2020193","article-title":"In vivo applications of single-chain Fv (variable domain) (scFv) fragments","volume":"2","author":"Monnier","year":"2013","journal-title":"Antibodies"},{"key":"10.1016\/j.bbrc.2026.153716_bib4","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153716_bib5","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.3390\/cancers14174206","article-title":"Single-chain fragment variable: recent progress in cancer diagnosis and therapy","volume":"14","author":"Mu\u00f1oz-L\u00f3pez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2026.153716_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/jcm10081685","article-title":"Ewing sarcoma\u2014diagnosis, treatment, clinical challenges and future perspectives","volume":"10","author":"Z\u00f6llner","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbrc.2026.153716_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1023\/A:1013148730966","article-title":"Second malignancies after ewing tumor treatment in 690 patients from a cooperative german\/austrian\/dutch study","volume":"12","author":"Paulussen","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2026.153716_bib8","first-page":"5134","article-title":"CD99 engagement: an effective therapeutic strategy for ewing tumors","volume":"60","author":"Scotlandi","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153716_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI36667","article-title":"CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis","volume":"120","author":"Rocchi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.153716_bib10","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/sj.onc.1209300","article-title":"Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells","volume":"25","author":"Kreppel","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.153716_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/HAB-180350","article-title":"Production and characterization of monoclonal antibodies against recombinant extracellular domain of CD99","volume":"27","author":"Thangaretnam","year":"2019","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.bbrc.2026.153716_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28965","article-title":"Redirecting the JAK-STAT signal blocks SARS-CoV-2 replication","volume":"95","author":"Augustine","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bbrc.2026.153716_bib13","doi-asserted-by":"crossref","first-page":"79925","DOI":"10.18632\/oncotarget.13160","article-title":"CD99 triggering induces methuosis of ewing sarcoma cells through IGF-1R\/RAS\/Rac1 signaling","volume":"7","author":"Manara","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.153716_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167402","article-title":"High-valency anti-CD99 antibodies toward the treatment of T cell acute lymphoblastic leukemia","volume":"434","author":"Romero","year":"2022","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.153716_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10616-009-9213-0","article-title":"A modified hybridoma technique for production of monoclonal antibodies having desired isotypes","volume":"60","author":"Apiratmateekul","year":"2009","journal-title":"Cytotechnology"},{"key":"10.1016\/j.bbrc.2026.153716_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256079","article-title":"Determination of variable region sequences from hybridoma immunoglobulins that target Mycobacterium tuberculosis virulence factors","volume":"16","author":"Foreman","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.153716_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12934-016-0419-5","article-title":"Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli","volume":"15","author":"Gaciarz","year":"2016","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.bbrc.2026.153716_bib18","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.3390\/ijms21176324","article-title":"Evolution of Escherichia coli expression system in producing antibody recombinant fragments","volume":"21","author":"Sandomenico","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153716_bib19","article-title":"Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia","volume":"29","author":"Vaikari","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bbrc.2026.153716_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.bbrc.2026.153716_bib21","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0002-9440(10)65707-0","article-title":"Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells","volume":"153","author":"Sohn","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2026.153716_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s43141-021-00264-6","article-title":"Hybridoma technology: advancements, clinical significance, and future aspects","volume":"19","author":"Mitra","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.153716_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/ilar.37.3.132","article-title":"Recombinant antibody technology","volume":"37","author":"Karn","year":"1995","journal-title":"ILAR J."},{"key":"10.1016\/j.bbrc.2026.153716_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/bioengineering10020122","article-title":"Bioengineering of antibody fragments: challenges and opportunities","volume":"10","author":"Pirkalkhoran","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.bbrc.2026.153716_bib25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1073\/pnas.77.4.2197","article-title":"Immunoglobulin chain loss in hybridoma lines","volume":"77","author":"K\u00f6hler","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2026.153716_bib26","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1038\/s41598-022-09324-4","article-title":"Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv","volume":"12","author":"Arslan","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.153716_bib27","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E. coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2026.153716_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jim.2014.04.012","article-title":"Blocking monocyte transmigration in vitro by a human antibody scFv anti-CD99","volume":"408","author":"Moricoli","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bbrc.2026.153716_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antib13010024","article-title":"Anti-CD99 antibody therapy triggers macrophage-dependent ewing cell death in vitro and myeloid cell recruitment in vivo","volume":"13","author":"O'Neill","year":"2024","journal-title":"Antibodies"},{"key":"10.1016\/j.bbrc.2026.153716_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fbinf.2025.1533983","article-title":"Unlocking the potential of in silico approaches in designing antibodies against SARS-CoV-2","volume":"5","author":"Subramaniam","year":"2025","journal-title":"Front Bioinform"},{"key":"10.1016\/j.bbrc.2026.153716_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.153716_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2026.153716_bib33","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2026.153716_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.153716_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/genes9030159","article-title":"CD99: a cell surface protein with an oncojanus role in tumors","volume":"9","author":"Manara","year":"2018","journal-title":"Genes"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26004808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26004808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:18:36Z","timestamp":1778707116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26004808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"alternative-id":["S0006291X26004808"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153716","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of single chain antibodies for targeting Ewing sarcoma surface marker CD99","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153716"}}